Vitaly Druker
A5058713336- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Acute Myeloid Leukemia Research
- interferon and immune responses
- Lung Cancer Research Studies
- Mosquito-borne diseases and control
- RNA modifications and cancer
- Blood Pressure and Hypertension Studies
- Sodium Intake and Health
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Hormonal Regulation and Hypertension
- Cardiac Structural Anomalies and Repair
- Thermoregulation and physiological responses
- Fuel Cells and Related Materials
- Mechanical Circulatory Support Devices
Integrated Statistics (United States)
2022-2025
AstraZeneca (United Kingdom)
2023
Abstract Purpose: Ataxia-telangiectasia mutated (ATM) is the most frequently DNA damage repair gene in non–small cell lung cancer (NSCLC). However, molecular correlates of ATM mutations and their clinical implications have not been fully elucidated. Experimental Design: Clinicopathologic genomic data from 26,587 patients with NSCLC MD Anderson, public databases, a de-identified nationwide (US-based) clinicogenomic database (CGDB) were used to assess co-mutation landscape, protein expression,...
Background: Endovascular renal denervation reduces blood pressure (BP). We explored an alternative approach to using radiofrequency energy delivered across the pelvis utilizing natural orifice of urethra and ureters. Methods: This open-label, single-arm feasibility study enrolled patients with uncontrolled hypertension despite antihypertensive drug therapy. The primary effectiveness endpoint was change in ambulatory daytime systolic BP (SBP) 2 months following pelvic denervation. Results: 18...
<b><i>Introduction:</i></b> We previously completed a trial of renal pelvic denervation for treating hypertension that reduced blood pressure by the 2-month primary endpoint. However, information on durability effectiveness is critical requirement device therapy and we now report data up to 12 months. <b><i>Methods:</i></b> This was an open-label, single-arm feasibility study in patients with increased despite taking average 2.7 medications....
<p>Supp Figure 2. ATM co-mutation enrichment analyses within cohorts.</p>
<p>Supp Table 3. ATM co-mutation enrichment analysis in KRAS mutant tumors, meta-analysis and within individual cohorts.</p>
<div>AbstractPurpose:<p><i>Ataxia-telangiectasia mutated</i> (<i>ATM</i>) is the most frequently mutated DNA damage repair gene in non–small cell lung cancer (NSCLC). However, molecular correlates of <i>ATM</i> mutations and their clinical implications have not been fully elucidated.</p>Experimental Design:<p>Clinicopathologic genomic data from 26,587 patients with NSCLC MD Anderson, public databases, a de-identified nationwide...
<p>Supp Figure 4. ATM variants, protein and mRNA expression.</p>
<p>Supp Figure 7. Immune checkpoint inhibitor (ICI) monotherapy vs with chemotherapy in ATM-mutated patients.</p>
<p>Supp Table 2. ATM co-mutation enrichment analysis, in meta-analysis and within individual cohorts.</p>
<div>AbstractPurpose:<p><i>Ataxia-telangiectasia mutated</i> (<i>ATM</i>) is the most frequently mutated DNA damage repair gene in non–small cell lung cancer (NSCLC). However, molecular correlates of <i>ATM</i> mutations and their clinical implications have not been fully elucidated.</p>Experimental Design:<p>Clinicopathologic genomic data from 26,587 patients with NSCLC MD Anderson, public databases, a de-identified nationwide...
<p>Supp Figure 5. Tumor mutational burden (TMB) in ATM mutant vs wild-type tumors.</p>
<p>Supp Figure 4. ATM variants, protein and mRNA expression.</p>
<p>Supp Figure 6. Clinical analyses in the FH-FMI CGDB cohort.</p>
<p>Supp Figure 9. ATM loss enhances STING signaling activation with chemotherapy in murine cell lines.</p>
<p>Supp Table 5. Flatiron Health-Foundation Medicine Clinicogenomic Database (FH-FMI CGDB) cohort characteristics, overall and stratified by treatment with chemotherapy along (Chemo), immune checkpoint inhibitor monotherapy (ICI), or combination ICI (ICI-chemo)</p>
<p>Supp Table 5. Flatiron Health-Foundation Medicine Clinicogenomic Database (FH-FMI CGDB) cohort characteristics, overall and stratified by treatment with chemotherapy along (Chemo), immune checkpoint inhibitor monotherapy (ICI), or combination ICI (ICI-chemo)</p>
<p>Supp Table 1. ATM mutations considered dysfunctional and supporting evidence</p>
<p>Supp Figure 9. ATM loss enhances STING signaling activation with chemotherapy in murine cell lines.</p>
<p>Supp Figure 8. Comparison of outcomes in ATM missense vs truncating mutations wild-type tumors the FH-FMI CGDB cohort.</p>
<p>Supp Table 2. ATM co-mutation enrichment analysis, in meta-analysis and within individual cohorts.</p>
<p>Supp Table 1. ATM mutations considered dysfunctional and supporting evidence</p>
<p>Supp Table 4. ATM co-mutation enrichment analysis in KRAS wild-type tumors, meta-analysis and within individual cohorts.</p>
<p>Supp Table 4. ATM co-mutation enrichment analysis in KRAS wild-type tumors, meta-analysis and within individual cohorts.</p>
<p>Supp Figure 8. Comparison of outcomes in ATM missense vs truncating mutations wild-type tumors the FH-FMI CGDB cohort.</p>